The chief research and medical affairs officer at the National MS Society discussed AI-enabled imaging, biomarkers of progression, women's health across the lifespan, and the Society's Campaign to End MS.
|Videos|November 3, 2020
Webinar: Differing Perspectives on Multiple Sclerosis Nursing Care
Author(s)NeurologyLive® Staff
A 2-part webcast series geared toward MS nursing professionals and patients.
Advertisement
This educational webcast features presentations by Denise Bruen, ANP-BC, MSN, MSCN; Stephanie Agrella, PhDc, MSN, RN, ANP-BC, MSCN; and Marie Namey, APRN, MSCN. This innovative program provides nurses and patients with evidence-based information on the latest disease-modifying therapies, as well as symptoms and the psychological impact of MS, in order to educate and improve the relationships between MS nursing professionals and their patients. Nursing professionals will earn 3 CE credits for completing the nursing program.
How to Claim Credit
- To complete the post-test, evaluation, and claim credit, go to:
https://www.highmarksce.com/mscare/ - Create a new account or log in with your user name and password*.
- Select the Enduring Materials tab, then select this activity from the listing and follow the instructions to complete the activity and receive your credit.
- *If you forgot your username or password, click on Forgot password. You will receive an email with a link to change your password.
Advertisement
Related to this article
A phase 2 trial found liposomal mitoxantrone hydrochloride had an acceptable safety profile and a potential trend toward fewer relapses in neuromyelitis optica spectrum disorder.
The phase 2 FENerations1 study is an open-label, single-arm, small-scale study evaluating fenebrutinib dosing in 8 to 12 children and adolescents with relapsing MS.
Data from the real-world, CONFIDENCE study found switching from intravenous to subcutaneous ocrelizumab was well tolerated in patients with relapsing and primary progressive MS.
Open-label extension data showed that disability trends observed with vidofludimus calcium during the double-blind period of the phase 2 CALLIPER trial persisted with continued treatment in progressive MS.
Early phase 1 data in 3 patients suggest CTA313, an allogeneic CD19/BCMA CAR-T, may stabilize disability with a manageable safety profile in progressive MS.
One-year data from the phase 3 AQUARELLE study found that divozilimab, an anti-CD20 antibody, reduced relapse risk in patients with neuromyelitis optica spectrum disorder.
Decade of OPERA Data Supports Early Ocrelizumab Treatment Initiation in Relapsing Multiple Sclerosis
A newly published 10-year analysis of the OPERA I and II trials reported that starting ocrelizumab 2 years earlier was associated with less disability accrual in relapsing MS, with no new safety signals.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Clene Submits NDA Seeking Accelerated Approval for ALS Drug
2
Early Data Show Dual-Targeting CAR-T Agent CTA313 Stabilizes Progressive Multiple Sclerosis
3
Real-World Data Show Switch to Subcutaneous Ocrelizumab Well Tolerated
4
CALLIPER Extension Data Show Sustained Disability Outcomes With Vidofludimus Calcium in Progressive MS
5